Determination of somatostatin receptors types 2A and 5 (SSTR-2A, SSTR-5) expression in neuroendocrine tumors (NETs) and neuroendocrine carcinoma (NECs) of various localizations and grade

#3191

Introduction: One of the main treatment options for this disease is SA,which bind SSTRs to the on the surface of neuroendocrine cells (NC) and block them.But SSTRs are not always present in NC

Aim(s): To determine the expression of SSTR-2A/5 in NETs and NECs tissue samples of different localizations and grade to assess the possibilities of SA treatment in particular groups of patients

Materials and methods: A retrospective analysis of 96 cases of patients from N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia. SSTR-2A/5 status was assessed by IHC-method. There were 72 patients with NETs G1-G3:G1-20,G2-40,G3–12.Primary focus:29–pancreas,12–small intestine, 5–stomach, 2–colon, 16–lung, 8– unknown primary. There were 24 patients with NECs.All of the gastrointestinal and pancreatic NETs was divided into 3 groups along with 2017-2019 World Health Organization (WHO) Classification

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Emelianova G, Artamonova E, Ushakov A, Delektorskaya V, Markovich A,

Keywords: neuroendocrine tumor, neuroendocrine carcinoma, somatostatin receptor,